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Abstract
Background: The Trypanosoma cruzi satellite DNA (satDNA) OligoC-TesT is a standardised PCR format for diagnosis of
Chagas disease. The sensitivity of the test is lower for discrete typing unit (DTU) TcI than for TcII-VI and the test has not been
evaluated in chronic Chagas disease patients.
Methodology/Principal Findings: We developed a new prototype of the OligoC-TesT based on kinetoplast DNA (kDNA)
detection. We evaluated the satDNA and kDNA OligoC-TesTs in a multi-cohort study with 187 chronic Chagas patients and
88 healthy endemic controls recruited in Argentina, Chile and Spain and 26 diseased non-endemic controls from D.R. Congo
and Sudan. All specimens were tested in duplicate. The overall specificity in the controls was 99.1% (95% CI 95.2%–99.8%)
for the satDNA OligoC-TesT and 97.4% (95% CI 92.6%–99.1%) for the kDNA OligoC-TesT. The overall sensitivity in the
patients was 67.9% (95% CI 60.9%–74.2%) for the satDNA OligoC-TesT and 79.1% (95% CI 72.8%–84.4%) for the kDNA
OligoC-Test.
Conclusions/Significance: Specificities of the two T. cruzi OligoC-TesT prototypes are high on non-endemic and endemic
controls. Sensitivities are moderate but significantly (p= 0.0004) higher for the kDNA OligoC-TesT compared to the satDNA
OligoC-TesT.
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Introduction
Trypanosoma (T.) cruzi is a kinetoplastid protozoan parasite and
the etiological agent of American trypanosomiasis or Chagas
disease. An estimated 8 million people are infected and more than
25 million are at risk of contracting the infection [1]. Chagas
disease is endemic in Latin America, but evolved to a global health
problem due to migration to other continents [2]. T. cruzi has a
broad host range including wild and domestic animals. The
parasite is primarily transmitted by infected haematophagous
Triatominae bugs. Additional transmission routes include blood
transfusion, organ transplantation, congenital infection, accidental
infection and consumption of contaminated food causing orally
transmitted outbreaks [3]. The initial acute phase lasts 6–8 weeks
and clinical symptoms are generally mild and non-specific. Also in
the chronic phase, the majority of the infected individuals remain
asymptomatic, but up to 30% develop cardiac and digestive
complications that can be fatal [4]. T. cruzi is monophyletic, but
genetically heterogeneous and divided in six discrete typing units
(DTUs): T. cruzi I to VI. The different DTUs have been associated
with specific geographical distribution, reservoirs, vectors, viru-
lence, clinical manifestation and susceptibility to drugs [5].
Accurate diagnosis of Chagas disease is challenging due to the
latent character of the infection [6]. The parasite load in the blood
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of acute phase patients is generally high enough to be detected by
microscopic analysis of blood smears or buffy coat in microhae-
matocrit capillaries. However, only 1 to 2% of all infected
individuals are actually diagnosed during this phase because of the
non-specific clinical manifestations [7]. In chronic patients, the
parasite load is often very low and diagnosis is mostly
accomplished by serological methods such as the indirect
immunofluorescence (IIF), indirect haemagglutination (IHA) and
enzyme-linked immunosorbent assays (ELISA). Sensitivity of
antibody detection tests is generally high, but false-positive results
occur due to cross-reactions with antibodies induced by other
microorganisms such as Leishmania spp. or T. rangeli [8]. T. rangeli is
closely related to T. cruzi and is non-pathogenic to man but shares
the same reservoir animals and vectors [9]. To increase specificity,
it is recommended to subject a specimen to at least two different
serological assays [7]. For post-treatment monitoring however, the
long-term persistence of specific antibodies, even after successful
treatment, makes serological tests less informative. In case of
congenital infections, serology can only be used after 6 to 8 months
of age, because of the presence of maternal antibodies in newborns
[7].
The polymerase chain reaction (PCR) has been presented as a
promising method for sensitive and specific detection of T. cruzi
parasites, especially in newborns [10] and during follow-up after
treatment [11]. Real-time PCR offers the possibility to quantify
the bloodstream parasite load, which could be of particular interest
to follow the response to trypanocidal drugs [12]. DNA targets
that have been most widely used in diagnostic PCR’s are the T.
cruzi minicircle kinetoplast DNA (kDNA) and the 195-bp satellite
DNA (satDNA) [13]. Recently, we reported the development of a
PCR dipstick assay for standardised detection of T. cruzi DNA in
biological samples [14]. This T. cruzi OligoC-TesT (Coris
BioConcept, Gembloux, Belgium) targets the satDNA sequence
[15]. PCR amplicons are visualised on a lateral flow device that
contains internal controls for the PCR reaction and for the
chromatographic migration. The phase I evaluation showed high
sensitivity and specificity on a diverse panel of biological samples
and indicated the potential of the T. cruzi OligoC-TesT as a
molecular diagnostic tool for Chagas disease [14]. However, the
analytical sensitivity of the T. cruzi OligoC-TesT was 100 to 1000
times lower for TcI compared to the other DTUs, which is
probably due to the lower copy number of the satDNA in TcI
[16].
A recent multicentre validation study assessed the diagnostic
accuracy of 48 different PCR tests, including the T. cruzi OligoC-
TesT. The study revealed highly heterogeneous results among the
different PCR tests and a sensitivity of 72% (n = 32) and specificity
of 60% (n = 10) of the T. cruzi satDNA OligoC-TesT [13].
To increase sensitivity without compromising on T. rangeli cross-
reactivity, a new OligoC-TesT prototype targeting a conserved
region of the T. cruzi minicircle kDNA was developed. To assess
their diagnostic accuracy in different endemic regions, we
evaluated both versions of the T. cruzi OligoC-TesTs in a multi-
cohort phase II study with 187 Chagas patients and 114 controls.
Methods
Ethics
Ethical clearance for the study was obtained from the ethics
committees of the Universidad de Chile, Fundacion Huesped
(Argentina) and Hospital Universitario Ramo´n y Cajal (Madrid,
Spain). Written informed consent was obtained from patients and
from non-diseased persons. Adult participants provided their own
consent and a parent or guardian provided consent for children.
All samples were anonymized.
DNA
Purified DNA from T. cruzi Cutia cl1 (TcI), TU18 cl93 (TcII),
M5631 cl5 (TcIII), Dog Theis (TcIV), MN cl2 (TcV) and CL
Brener (TcVI) was obtained from the DNA reference bank at the
London School of Hygiene and Tropical Medicine (LSHTM,
UK). DNA from L. chagasi and three T. rangeli isolates LEM2953,
P13 and SJMC2 was obtained from the DNA reference bank at
the Institute of Tropical Medicine Antwerp (ITM, Belgium).
Concentrations were measured using the nanodrop ND-1000 UV-
Vis spectrophotometer (NanoDrop Technologies, Wilmington,
USA) and the DNA was stored at 220uC. To assess the lower
detection limits of the T. cruzi OligoC-TesTs, tenfold serial
dilutions of parasite DNA, ranging from 200 pg to 0.002 fg DNA
per test reaction, were prepared in water (Accugene, Lonza,
Belgium) containing 0.1 mg/ml bovine serum albumin (Promega,
Madison, Wis.). Archived DNA from blood of diseased non-
endemic control persons was obtained from the biobank at ITM:
15 confirmed visceral leishmaniasis patients from Sudan and 11
confirmed gambiense sleeping sickness patients from D.R. Congo.
Study participants and reference tests
In this prospective study, participants were classified as healthy
endemic controls and Chagas disease patients based on the results
of the reference tests, as described below. Exclusion criteria for
participation in the study were children below 12 years of age,
serious illness and not signing the informed consent form.
Healthy endemic controls were recruited from the blood bank of the
Clinical Hospital at the University of Chile in 2004 and 2011.
Study participants were classified as healthy endemic controls if
they had no history of Chagas disease, showed no clinical
symptoms and their serum was negative in T. cruzi ELISA and IIF.
Chagas disease patients were recruited in the Santiago Metropol-
itan Region in Chile in 2009; in Salta province North-West
Argentina between 2008 and 2010; and at the Hospital Ramo´n y
Cajal in Madrid, Spain in 2011. The patients recruited in Madrid
were immigrants originating from Bolivia. Study participants were
classified as Chagas disease patients if positive test results were
obtained in ELISA and IHA (Argentina) or ELISA and IIF (Spain
and Chile). Specifications of the reference tests are given in table 1.
Author Summary
Accurate diagnosis of Chagas disease is challenging due to
the latent character of the infection and the low parasite
load in the blood. Molecular tests such as the polymerase
chain reaction (PCR) detect the parasite’s DNA and are
generally very sensitive and specific. In this study we
evaluated two prototypes of a standardized PCR diagnos-
tic kit: the satellite DNA (satDNA) OligoC-TesT and the
kinetoplast (kDNA) OligoC-TesT. Sensitivities and specific-
ities of both tests were estimated in a multi-cohort phase II
evaluation study with 187 chronic Chagas patients and 88
healthy endemic controls from Argentina, Chile and Spain,
and 26 non-endemic controls from D.R. Congo and Sudan
with potentially cross-reacting diseases. Specificities in the
control persons were high (.97%) and the sensitivity of
the kDNA OligoC-TesT (79.1%) was significantly higher
than of the satDNA OligoC-Test (67.9%). In a next phase,
the kDNA OligoC-TesT should be evaluated in specific
niches where standard serological tools have their limita-
tions, e.g. follow-up after treatment and diagnosing
newborns and HIV co-infected patients.
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Blood collection and DNA extraction
Blood was collected and instantly mixed with an equal volume
of guanidium EDTA buffer (GEB; 6M guanidium chloride, 0.2 M
EDTA, pH 8.0), stored at 4uC and 1 mL aliquots were shipped to
ITM Antwerp, Belgium. Upon receipt, DNA was extracted in
duplicate from 200 mL lysed blood using the QIAamp DNA blood
mini kit (Qiagen, Hilden, Germany) for the cohort recruited in
Chile in 2004 and the High Pure PCR Template Preparation Kit
(Roche Applied Sciences, IN, USA) for the other blood specimens.
DNA extractions were done according to the manufacturer’s
instructions but with some modifications for the High Pure PCR
Template Preparation Kit. Briefly, 200 mL of the blood/GEB
sample were mixed with 600 mL binding buffer, 100 mL proteinase
K and 200 mL isopropanol. The mixture was loaded onto a filter
tube pre-packed with glass fibers, followed by extensive washing as
described in the kit’s manual. Finally, the DNA was eluted with
200 mL elution buffer that was preheated at 70uC. DNA was
stored at 220uC immediately after extraction.
Index tests
SatDNA OligoC-TesT. The T. cruzi satDNA OligoC-TesT (Coris
BioConcept) was performed as previously described by Deborg-
graeve et al. [14]. The OligoC-TesT kit contains all components
needed for performing the PCR and the product analysis by
dipstick. Briefly, sequences of the oligonucleotides were: Tc-Sat-F
primer 59CACTCTCTGTCAATGTCTGTTTGCGTG-39 and
Tc-Sat-R primer 59-GAAATTCCTCCAAGCAGCGGATA-39;
T. cruzi detection probe 59-TGGACACCAAACAACCC-39; and
internal control (IC) probe 59-AGGGTCTACTGGGT-
TACCTG-39. To the 47.3 mL satDNA Ampli-Mix (Coris
BioConcept), 2.5 mL sample DNA and 1 unit Hot Star Taq
polymerase (Qiagen) were added and the mixture was subjected to
thermal cycling as follows: 94uC for 15 minutes, 40 cycles of 94uC
for 20 seconds, 65uC for 20 seconds and 72uC for 20 seconds, and
a final extension at 72uC for 1 minute. Forty mL denaturated
amplification product were mixed with an equal volume of
OligoStrip running buffer preheated at 55uC followed by dipping
the T.cruzi satDNA Oligo-Strip into the solution. Test results were
read qualitatively after 5 minutes, as previously described [14].
kDNA OligoC-TesT. The T. cruzi kDNA OligoC-Test (Coris
BioConcept) is identical to the satDNA OligoC-TesT except for
the following specifications. Primers target the conserved region of
the T. cruzi minicircle and have the following sequences: TcK-F
59-GTTTTGGGAGGGGCGTTCAA-39 and TcK-R 59-TA-
TATTACACCAACCCCAATCGAACC-39. The detection probe
was 59-AAATAATGTACGGGGGAGATGCATG-39 and the
sequences of the IC and IC detection probe were identical as for
the satDNA OligoC-TesT except for the IC that contained specific
primer sites for TcK-F and TcK-R. Five mL sample DNA and 2
units of Hot Diamond Taq DNA polymerase (Eurogentec, Lie`ge,
Belgium) were added to 44.6 mL T. cruzi kDNA Ampli-mix (Coris
BioConcept) and the reaction mixture was subjected to thermal
cycling as follows: 95uC for 5 minutes, 40 cycles of 94uC for
20 seconds, 63uC for 20 seconds and 72uC for 20 seconds, and a
final extension at 72uC for 1 minute. Forty mL denaturated
amplification product were mixed with an equal volume of
OligoStrip running buffer (Coris BioConcept) preheated at 55uC
followed by dipping the T.cruzi kDNA Oligo-Strip into the
solution. Test results were read after 10 minutes incubation. The
executor of the index tests was one of the authors (KDW), a
trained molecular biologist who was blinded to the results of the
reference tests. The reference tests were performed at the sites of
sample collection and the index tests were performed at ITM
Antwerp.
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Statistical analysis
Sensitivities and specificities of the OligoC-TesTs were
calculated from data entered into contingency tables. Differences
in sensitivity and specificity between the two tests were estimated
by the McNemar test. Repeatabilities of the tests were
determined using the Kappa index. All calculations were
estimated at a 95% confidence interval (95% CI) using Wilson’s
score.
Results
Study participants
We recruited 88 healthy endemic controls and 187 Chagas
patients between 2009 and 2012. Demographic characteristics of
the study participants are presented in table 1. Time between
sample collection and conducting the index tests was maximum six
months.
Analytical sensitivity and specificity
The analytical sensitivity and specificity of the T. cruzi satDNA
and kDNA OligoC TesTs were evaluated on tenfold serial
dilutions of DNA from reference T. cruzi strains representing the 6
DTUs and from 3 T. rangeli strains. Serial dilutions were prepared
in duplicate. Considering that one parasite contains about 100 fg
of DNA and taking into account the dilution factors during DNA
extraction (8006 for the satDNA OligoC TesT and 4006 for the
kDNA OligoC TesT), the detection limit of each test was
expressed as the number of parasites per mL of blood that yielded
a positive signal in both repetitions. An overview of the analytical
sensitivities and specificities of the two OligoC-TesTs is presented
in figure 1. Generally, the OligoC-TesT targeting the kDNA
showed a higher analytical sensitivity (lower detection limit: 0.4 to
40 parasites/ml blood) than the OligoC-TesT targeting the
satDNA (lower detection limit: 4 to 4000 parasites/ml blood).
On the serial dilutions of the T. rangeli DNA the two tests showed
lower detection limits of 400,000 parasites per mL of blood or
higher. No cross-reaction of the satDNA OligoC-TesT with
Leishmania DNA was observed in our proof-of-concept study
reported in 2009 [14]. In the current study, we analyzed 5 ng
L. chagasi DNA with the kDNA OligoC-TesT and the test
remained negative.
Diagnostic accuracy (table 2)
Sensitivities, specificities and repeatability of the T. cruzi
satDNA and kDNA OligoC-TesTs were calculated on the 26
diseased non-endemic controls, 88 healthy endemic controls and
187 Chagas patients.
Both OligoC-TesTs showed high specificity on the diseased
non-endemic and healthy endemic controls, ranging from 94.3%
to 100%. The overall specificities in these participant groups were
99.1% (95% CI 95.2%–99.8%) for the satDNA OligoC-TesT and
97.4% (95% CI 92.6%–99.1%) for the kDNA OligoC-TesT. No
significant difference in specificity was observed between the two
tests (p= 0.317).
Considering all Chagas patients recruited in the study, the
kDNA OligoC-TesT showed a significantly higher sensitivity
(79.1%, 95% CI 72.8%–84.4%) than the satDNA OligoC-TesT
(67.9%, 95% CI 60.9%–74.2%) (p= 0.0004). Sensitivities of the
Figure 1. Analytical sensitivity and analytical specificity of the T. cruzi satDNA OligoC-TesT and kDNA OligoC-TesT on DNA from 6
T. cruzi and 3 T. rangeli reference strains. DTU=discrete typing unit, NA= not applicable.
doi:10.1371/journal.pntd.0002633.g001
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OligoC-TesTs on the Chagas patients from Argentina were
generally low and ranged from 49.3 to 63.0%. The overall
repeatability of the kDNA OligoC-TesT (kappa = 0.85, 95% CI:
0.74–0.96) was higher than of the satDNA OligoC-TesT
(kappa = 0.66, 95% CI: 0.54–0.77).
Discussion
Recently, the T. cruzi satDNA OligoC-TesT was developed as a
standardised format for molecular detection of T. cruzi satDNA
[14]. Here, we report on the development of a second prototype,
the T. cruzi kDNA OligoC-TesT, and the phase II evaluation of
both tests on human target populations in different endemic
regions.
With representative strains of the 6 T. cruzi DTUs, we observed
that the T. cruzi kDNA OligoC-TesT, detecting between 0.4 and
40 parasites/mL which corresponds with 0.02 to 2 fg DNA per
mL, had a higher (DTU I, IV, V and VI) or equal (DTU II and III)
analytical sensitivity than the T. cruzi satDNA OligoC-TesT.
These values are comparable to the results obtained in the PCR
standardisation study of Schijman et al. [13] wherein the authors
reported detection limits between 0.01 and 10 fg/mL for the four
best performing PCR’s. Both OligoC-TesTs amplified purified
T. rangeli DNA, but required between 102 and 107 times more
template DNA than for T. cruzi. For the satDNA OligoC-TesT,
this is probably due to the number of satDNA repeats being about
1000 times lower in T. rangeli than in T. cruzi [17]. For the kDNA
OligoC-TesT, the higher detection limit for T. rangeli, was
obtained by one base pair mismatch between the reverse primer
and the kDNA sequence of T. rangeli.
The diagnostic specificity of the two OligoC-TesTs was 100%
on diseased non-endemic controls (Sudan and D.R. Congo) and
between 94% and 99% on healthy endemic controls (Chile). A
systematic review of the diagnostic accuracy of PCR for chronic
Chagas disease showed that most PCR evaluation studies found
similar high specificities [18]. In a next step, prospective evaluation
studies with consecutive enrolment of suspected cases should be
conducted to have a more accurate estimation of the specificity.
When considering all Chagas patients recruited in the study,
sensitivities of the OligoC-TesTs were moderate (79.1% for the
kDNA OligoC-TesT and 67.9% for the satDNA OligoC-TesT),
but comparable with reported sensitivities for other T. cruzi PCR’s
applied on chronic Chagas patients. In the review cited above,
sensitivities ranging from 50 to 90% were observed [18]. Similar
sensitivities, from 63% to 69%, were reported for the four best
performing molecular diagnostics in the multicentre validation
study conducted by Schijman et al. [13]. Particularly during the
chronic phase, T. cruzi parasites circulate in very low and variable
numbers in the bloodstream [19,20]. Therefore, although PCR
appears to be a sensitive method for the detection of T. cruzi DNA,
it may remain negative in patients with very low or intermittent
parasitaemia. Recovering DNA from larger blood volumes than
the 200 ml used in this study would enhance sensitivity. The
sensitivities of the two OligoC-TesTs greatly varied between the
different cohorts. We observed a lower sensitivity of the OligoC-
TesTs in the patients from Argentina compared to the patients
from Chile and Spain. All blood samples in the study were
collected, stored and shipped following a standardized procedure.
We checked for degradation of the DNA in the Argentinean blood
samples using primers targeting the human cytochrome b gene
[21]. All samples were positive in this control PCR indicating no
DNA degradation (data not shown). Compared to the other
cohorts, the Argentinean patients showed a lower percentage of
patients with Chagas symptoms which may be related with
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parasite load. Recently, Moreira et al. estimated the parasite loads
in the blood of chronic Chagas patients from Argentina, Brazil and
Colombia [22]. The median parasite load in the patients from
Argentina was 1.93 parasites per mL of blood which was lower
than patients from Colombia but higher than from Brazil. Genetic
differences of parasite strains and/or DTUs might influence
parasitaemia in man and partially explain the discrepancies of
PCR sensitivity between cohorts from different endemic areas.
However, no association between DTU and parasitaemia in the
blood of patients has been reported yet [23]. In addition, T. cruzi
DTUs vary in DNA gene copy number, thus harbouring a
variable number of repeats of the PCR targets. Elias et al.
described that the satDNA sequences can be 4 to 6 times more
abundant in one DTU compared to another [16]. Since DTU
typing in the specimens in our study was not performed, no
conclusions can be made regarding this aspect. In view of the high
sensitivity and PCR dependence of the OligoC-TesTs it is essential
to use standard precautions during collection of blood and DNA
extractions to avoid cross contamination between samples, and to
include sufficient negative controls to detect any such contamina-
tion.
The overall repeatability of the kDNA OligoC-TesT was good
(kappa = 0.85) and higher than of the satDNA OligoC-TesT
(kappa = 0.66). Repeatabilities of the OligoC-Tests are linked to
the detection limit, thus sensitivity, which was also higher for the
kDNA OligoC-TesT. Therefore, moderate repeatabilities might
be caused by the target DNA content in the samples that is
situated too close to the lower detection limits of the tests.
In conclusion, the diagnostic accuracies of two standardised
PCR formats, the satDNA OligoC-TesT and the kDNA OligoC-
TesT, were evaluated in a multi-cohort study on 301 persons from
various endemic and non-endemic countries. The specificities of
the two tests were high in non-endemic controls as well as healthy
endemic controls. The kDNA OligoC-TesT prototype showed a
significantly higher sensitivity compared to the satDNA OligoC-
TesT. However, it is unlikely that the OligoC-TesTs will play a
major role in the diagnosis of chronic Chagas disease because of
their low sensitivity compared to standard serological tests.
Furthermore, the OligoC-TesTs are restricted to laboratories
with PCR facilities, trained personnel and infrastructures that
reduce the risk of PCR contamination. Their impact outside the
main health centers will thus be limited. In a next phase, the
kDNA OligoC-TesT should be evaluated in specific niches where
standard serological tools have their limitations, e.g. diagnosing
newborns and HIV co-infected patients and follow-up after
treatment.
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